ArticleThe Journal of biological chemistry2026
ERα/SIRT1 signaling mediates the metabolic regulatory benefits of pterostilbene.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pterostilbene (PTS), a more bioavailable analog of resveratrol (RES), is a promising natural metabolic regulator for improving metabolic health. The metabolic regulatory benefits of RES are believed to be associated with SIRT1 activation. However, the direct activation of SIRT1 by RES was proven to be an in vitro artifact. Here, we demonstrate that PTS is a more potent metabolic regulator than RES. More significantly, we have identified estrogen receptor α (ERα) as the intermediate signaling mediating SIRT1 expression by both RES and PTS. First, RES and PTS function as ERα agonists to stimulate Sirt1 transcription. Second, RES and PTS act as stabilizers of ERα-SIRT1 interaction, blocking ubiquitination and thereby enhancing their protein stability. Third, RES and PTS promote ERα deacetylation, subsequently increasing ERα transactivation. Finally, skeletal muscle-specific ERα knockout attenuates the metabolic regulatory benefits of PTS. Together, our study demonstrates that PTS is a more potent metabolic regulator than RES by activating the ERα/SIRT1 signaling.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.